Background
==========

Methylmercury (MeHg) is a well-documented neurotoxicant, and prenatal exposures are therefore of particular concern \[[@B1],[@B2]\]. The main sources of exposure are seafood and freshwater fish \[[@B3]\]. Thus, MeHg exposures vary with dietary habits, contamination levels, and species availability. While the distribution of MeHg exposures has been studied in substantial detail in the United States \[[@B4]\], only scattered information is available on MeHg exposures in Europe.

Because the critical effect of MeHg exposure is developmental brain toxicity, exposures among women of reproductive age groups are of primary concern \[[@B5],[@B6]\]. As has previously been determined in regard to lead exposure \[[@B7]\], developmental MeHg exposure is linked to a loss in Intelligence Quotient (IQ), with associated lower school performance and educational attainment, thereby leading to long-term impacts on societal benefits of pollution abatement \[[@B8]\]. These consequences may be expressed in terms of economic impacts, as has been demonstrated in United States \[[@B9],[@B10]\]. However, few economic evaluations have been performed in Europe \[[@B8],[@B11],[@B12]\], primarily because of the lack of exposure data.

Based on harmonised protocols developed in COPHES \[[@B13]\], the DEMOCOPHES project has just completed a multi-country study of hair-mercury concentrations in women of reproductive age groups in 17 European countries. In conjunction with literature data, we now utilise the exposure data to generate estimates of economic impacts of MeHg exposures in Europe.

The economic assessment relies on several assumptions. The hair-Hg concentrations is used as the main exposure indicator in this study, and any blood-based measurements also considered are expressed in terms of hair-mercury using a conversion factor of 250 \[[@B14],[@B15]\]. In regard to the dose-response function (DRF), a linear model is usually the default \[[@B14]\], although it may not necessarily provide the best statistical fit to the data \[[@B16]\]. We therefore used the linear slope as the primary DRF and then conducted a sensitivity analysis using the log function, where each doubling of exposure above the background causes the same deficit of 1.5 IQ points \[[@B10]\].

With regard to background exposures and the possible existence of a threshold, the U.S. EPA's Reference Dose (RfD) of 0.1 μg/kg body weight/day corresponds to a hair-Hg concentration of about 1 μg/g hair \[[@B14]\]. Updated calculations \[[@B17]\] resulted in an adjusted biological limit about 50% below the recommended level, corresponding to 0.58 μg/g hair. The validity of this lower cut-off point below the RfD is supported by recent studies of developmental neurotoxicity at exposure levels close to the background \[[@B18]-[@B21]\]. We assumed that, below the 0.58 μg/g cut-off point, only negligible adverse effects would exist. As additional reference point, we use a tolerable limit proposed by the World Health Organization (WHO), which corresponds to a hair-Hg concentration of approximately 2.5 μg/g \[[@B22]\]. This limit takes into account the possible compensation of MeHg toxicity by beneficial nutrients in seafood \[[@B22]\].

Methods
=======

Exposure information
--------------------

DEMOCOPHES is a cross-sectional survey of European population exposure to environmental chemicals. The human exposure biomarkers included the hair-mercury concentration and was collected in 17 European countries based on children aged 6--11 years and their mothers. A common European protocol, developed by the COPHES project, was followed in each country. The main inclusion and exclusion criteria were (1) residence in the study area for at least five years, and (2) not having metabolic disturbances. The period of sampling was September 2011 to February 2012. A total of 1,875 child-mother pairs were recruited from urban and rural communities in the participating countries, while excluding exposure hot-spots. Major efforts were carried out to achieve high quality and comparability of data. Standard operational procedures for total mercury concentrations in hair were developed and validated by the Laboratory of Environmental Toxicology in Spain, to ensure comparable measurements, which included a strict quality assurance programme, in which seventeen European laboratories participated. Each DEMOCOPHES partner contributed information to allow estimation of the underlying distribution of exposures in the population, where rural and urban results were merged. In addition, each partner provided the frequencies of results above the cut-off levels of 0.58 μg/g, 1.0 μg/g, and 2.5 μg/g. The latter corresponds to WHO's tolerable limit, which takes into account likely toxicity compensation by beneficial nutrients in seafood \[[@B22]\].

Additional information on MeHg exposures in Europe was obtained to complement the DEMOCOPHES data. Thus, information of similar quality was extracted from published articles (Miklavčič, unpublished data), and distribution information from comparable studies was obtained from Belgium, Denmark, France, Norway, Slovenia, and the United Kingdom. As explained below, missing information was calculated assuming a log-normal distribution of the exposures.

Exposure distributions
----------------------

Using the number of births in 2008 and the observed hair-Hg concentrations, we estimated the number of births exceeding the three exposure limits for each country and obtained the sum for all of the EU. For missing EU member states, MeHg exposures were assumed to be the same as a neighbouring country. The year 2008 was chosen as the closest to the time during which the exposure data had been collected, and it allowed complete information for the calculations envisaged. Due to the existence of sampling uncertainty, "smoothed" proportions exceeding the three limits were calculated assuming log-normal distributions. Because log-transformed concentrations would follow a normal distribution, the parameters in the log-normal distributions could be estimated by standard normal distribution methods. Each data set included probabilities (prob) for being below specific percentiles (perc). The parameters in the logarithmic distributions were therefore obtained as the intercept and slope when regressing log(perc) on Φ^-1^(prob), where Φ is the cumulative distribution function of the standard normal distribution. Using the total numbers of births in 2008, numbers of births exceeding the three cut-off limits in each country were calculated from observed and smoothed distributions.

Calculation of IQ benefits
--------------------------

A linear dose-response function was applied as the default model \[[@B14]\]. Thus, as a 1 μg/L increase of the cord-blood mercury concentration is associated with an average adverse impact on IQ of 0.093 times the standard deviation (which is standardised to be 15), each increase in the maternal hair-mercury by 1 μg/g is associated with an average loss of 0.465 IQ points \[[@B10]\]. This slope is based on a range of neuropsychological tests and subtests administered in the Faroe Islands study at age 7 years \[[@B23]\]. As some recent studies \[[@B18]-[@B21]\] suggest MeHg-associated deficits close to or below the cut-off level of 0.58 μg/g hair, the calculations may represent an underestimate. In addition, the slope may be steeper at low exposure levels. Thus, a log model was used for sensitivity analyses. In this model, a doubling in prenatal MeHg exposures is associated with a delay in development of 1.5--2 months at age 7, which corresponds to about 10% of the standard deviation, i.e. 1.5 IQ points \[[@B1]\]. Again, we applied this slope for exposures above the 0.58 μg/g the cut-off point.

To estimate the benefits at exposures above the cut-off point, we calculated the average hair-mercury concentration in women exceeding 0.58 μg/g based on 1,000,000 simulations from the estimated log-normal distribution (as described above). After deduction of the 0.58 μg/g and multiplication by the slope factor, an average IQ benefit was obtained. This amount was then multiplied by the annual number of births exceeding the cut-off level. A similar calculation was made in the logarithmic dose-response model except that here we calculated the average log-transformed mercury concentration in women exceeding 0.58 μg/g, deducted log(0.58) and multiplied by the slope factor of the logarithmic dose-response model (1.5/log(2)).

Annual benefits of exposure reduction
-------------------------------------

The major component of the social costs incurred by an IQ reduction is loss of productivity and thus a lower earning potential \[[@B9],[@B24]\]. The economic consequence of prenatal exposure to MeHg is valued as the lifetime earning loss per person. We assumed singleton births only, so that the number of women was equal to the cohort size. We also assumed that IQ deficits present at age 7 years or preschool ages are permanent \[[@B25]\]. The estimated individual benefits are the avoided lifetime costs using 2008 data (slightly lower benefits are obtained if referring to more recent years, and benefits are only minimally affected by subsequent membership of the Euro zone). The benefit estimates originate from the 2008 figure of €17,363 per IQ point as recently calculated for France based on data from the United States \[[@B24]\]. For the various European countries involved, this value is adjusted for differences in purchasing power. While simple currency exchange conversion and Gross Domestic Product (GDP) per capita do not adjust for price differences, Purchasing Power Parity (PPP) conversion rates allow for comparison based on a common set of average international prices \[[@B26],[@B27]\]. We also carried out the calculations after adjustment for productivity as the ratio of PPP-adjusted real GDP/capita in each country in relation to the US as a reference. The estimated value of an IQ point then takes into account the impact of labour costs and productivity (Additional file [1](#S1){ref-type="supplementary-material"}).

Results
=======

Table  [1](#T1){ref-type="table"} and Additional file [2](#S2){ref-type="supplementary-material"} show summary information on MeHg exposures in the European countries covered by DEMOCOPHES or other exposure studies. There is a clear trend from north and east to southern countries, most likely due to differences in dietary habits and availability of large fish species from the Mediterranean (the sources of exposure were not considered in the present study). In Table  [1](#T1){ref-type="table"}, exposures in Austria were assumed to be similar to those in Germany, as suggested by available data \[[@B28]\]. Exposure information from the Flemish part of Belgium \[[@B29],[@B30]\] do not differ much from the national data obtained in DEMOCOPHES, which were therefore used for the calculations. The Flemish data were used to represent exposures in The Netherlands. In the absence of exposure data from Estonia, Finland, Latvia, and Lithuania, the DEMOCOPHES exposure information from Sweden was applied. National data from France are available \[[@B31]\] and have been used in recent economic calculations \[[@B8]\]. Data for Croatia and Greece were obtained from a recent birth cohort study \[[@B32]\]. Two exposure studies had been carried out in Italy, one in the northeast \[[@B32]\] and one in Naples \[[@B33]\], and a joint distribution was therefore used to obtain national exposure distributions that would also apply to Malta. Thus, a log-normal distribution was first fitted to each Italian data subset, and then the parameters of a joint log-normal distribution were determined as the mean of the parameters for the two distributions. Recent results from the Norwegian national birth cohort were used for this country \[[@B34]\]. As DEMOCOPHES data from the United Kingdom covered only a small rural sample, we relied on data on blood-mercury in pregnant women obtained from the ALSPAC birth cohort study in the 1990s \[[@B35]\]. Additional exposure data from Ukraine \[[@B36]\] supported the notion that MeHg exposures in Eastern Europe are low, with only small percentages exceeding the cut-off level, but this study was considered too small to be used for detailed calculations. The same applied to several other sources identified (Miklavčič, unpublished data).

###### 

**Annual numbers of births and numbers exceeding three cut**-**off limits**, **as indicated by hair**-**mercury analyses** (**in μg/g**) **in population samples in European countries**

  **Country**^**a**^   **Annual number of births** (**2008**)   **Number of samples**^**b**^   **Above 0**.**58 μg/g**   **Above 1**.**0 μg/g**   **Above 2**.**5 μg/g**                     
  -------------------- ---------------------------------------- ------------------------------ ------------------------- ------------------------ ------------------------ --------- ------- ---------
  Austria              77,800                                   NA                             (6.7)                     5,213                    (0.8)                    622       \(0\)   0
  Belgium              127,200                                  129                            28.7                      36,506                   9.3                      11,830    0       0
  242^c^               23.2                                     29,510                         7.2                       9,158                    0                                          
  Bulgaria             77,700                                   NA                             (4.2)                     3,263                    (1.2)                    932       (0.8)   622
  Croatia              43,800                                   234^d^                         52.0                      22,776                   22.0                     9,636     4.7     2,059
  Cyprus               9,200                                    60                             36.7                      3,376                    18.3                     1,684     3.3     304
  Czech Republic       119,600                                  120                            5.0                       5,980                    0.8                      957       0       0
  Denmark              65,000                                   145                            36.6                      23,790                   13.1                     8515      0.7     455
  Estonia              16,000                                   NA                             (10.0)                    1,600                    (2.0)                    320       \(0\)   0
  Faroe Islands        675                                      505^e^                         62.6                      423                      30.2                     204       5.3     36
  Finland              59,500                                   NA                             (10.0)                    5,950                    (2.0)                    1,190     \(0\)   0
  France               829,300                                  126^f^                         44.0                      364,892                  14.51                    120,331   0.61    5,059
  Germany              682,500                                  120                            6.7                       45,728                   0.8                      5,460     0       0
  Greece               118,300                                  454^d^                         78                        92,274                   57                       67,431    14      16,562
  Hungary              99,100                                   120                            0.83                      823                      0                        0         0       0
  Ireland              74,000                                   120                            10.8                      7,992                    2.5                      1,850     0       0
  Italy                576,700                                  891^d^ + 115^g^                (65.6)                    378,315                  (36.8)                   212,226   (5.7)   32,872
  Latvia               23,834                                   NA                             (10.0)                    2,383                    (2.0)                    477       \(0\)   0
  Lithuania            35,100                                   NA                             (10.0)                    3,510                    (2.0)                    702       \(0\)   0
  Luxembourg           5,600                                    55                             32.7                      1,831                    18.2                     1,019     0       0
  Malta                4,100                                    NA                             (65.6)                    2,690                    (36.8)                   1,509     (5.7)   234
  Netherlands          184,600                                  NA                             (23.2)                    42,827                   (7.2)                    13,291    \(0\)   0
  Norway               60,500                                   119^h^                         27.7                      16,759                   5.9                      3,570     0       0
  Poland               414,500                                  120                            1.7                       7047                     0                        0         0       0
  Portugal             104,600                                  120                            90.8                      94,977                   57.5                     60,145    8.3     8,682
  Romania              221,900                                  120                            4.2                       9,320                    1.2                      2,663     0.8     1,775
  Slovakia             57,400                                   129                            5.43                      3,117                    0.8                      459       0       0
  Slovenia             21,800                                   156                            22.0                      4,796                    7.7                      1,679     1.9     414
  Spain                519,800                                  120                            88.5                      460,023                  74.2                     385,692   31.7    164,777
  Sweden               109,300                                  100                            10.0                      10,930                   2.0                      2,186     0       0
  Switzerland          76,700                                   120                            5.0                       3,835                    2.1                      1,611     0       0
  United Kingdom       794,400                                  4134^h^                        31.0                      246,264                  5.1                      40,200    0       0
  Total EU (27)        5,400,000                                                                                         1,865,416                                         903,169           231,754

Exposures in EU countries without recent data are estimated from neighbouring countries (modelled results not based on observed distributions are given in parenthesis).

^**a**^ For countries without available exposure data (for number of samples, NA denotes not available), data from a neighbouring country have been applied to allow EU-wide estimates, and frequencies are given in parenthesis. This applies to Austria (data from Germany were used), Bulgaria (Romania), Netherlands (Flanders \[[@B30]\]), and Estonia, Finland, Latvia, and Lithuania (Sweden); ^b^ All data are from DEMOCOPHES, unless otherwise noted; ^c^\[[@B30]\]; ^d^\[[@B32]\]; ^e^ Pal Weihe, unpublished data; ^f^\[[@B31]\]; ^g^\[[@B33]\]; ^h^ Jean Golding, pers.comm.

The estimated number of annual births in the EU that exceed the 0.58 μg/g cut-off is about 1.8 million (Table  [1](#T1){ref-type="table"}, Additional file [3](#S3){ref-type="supplementary-material"}). The EPA limit is exceeded in about 900,000 births, and the WHO limit in 200,000 births within the EU. As each study is subject to sampling uncertainty, log-normal distribution models showed similar, though sometimes slightly higher, proportions exceeding the 0.58 cut-off level (Table  [2](#T2){ref-type="table"}). The data from Eastern European countries and from Croatia, the Faroe Islands, Norway, and Switzerland suggest that, within Europe, the great majority of births exceeding the various limits occur in EU member states.

###### 

**Annual number of births with excess exposure**, **average hair**-**Hg concentration**, **IQ benefit from prevention of excess exposure**, **and the value of the IQ benefits**

  **Country**      **Number of births above 0**.**58 μg/g**   **Average concentration above 0**.**58 μg/g**   **Benefit in IQ points**   **Value of 1 IQ point(Euro)**   **Total benefit(million Euro)**                      
  ---------------- ------------------------------------------ ----------------------------------------------- -------------------------- ------------------------------- --------------------------------- -------- --------- -----------
  Austria          3,812                                      5,213                                           0.917                      597                             817                               16,044   9.6       13.1
  Belgium          39,686                                     36,506                                          0.939                      6,625                           6,094                             16,458   109.0     100.3
  Bulgaria         3,186                                      3,263                                           1.455                      1,296                           1,328                             7,529    9.8       10.0
  Croatia          21,769                                     22,776                                          1.355                      7,845                           8,208                             11,320   88.8      92.9
  Cyprus           3,514                                      3,376                                           1.311                      1,195                           1,148                             13,747   16.4      15.8
  Czech Republic   5,143                                      5,980                                           0.847                      639                             742                               10,797   6.9       8.0
  Denmark          22,815                                     23,790                                          1.027                      4,742                           4,945                             20,220   95.9      100.0
  Estonia          1,840                                      1,600                                           0.846                      228                             198                               10,339   2.4       2.0
  Faroe Islands    406                                        423                                             1.323                      140                             146                               20,220   2.8       2.9
  Finland          6,843                                      5,950                                           0.846                      846                             736                               17,288   14.6      12.7
  France           405,528                                    364,892                                         0.989                      70,186                          69,397                            17,363   1,218.6   1,204.9
  Germany          33,443                                     45,728                                          0.917                      5,241                           7,166                             15,292   80.1      109.6
  Greece           94,403                                     92,274                                          1.563                      50,131                          49,000                            13,201   661.8     646.9
  Hungary          892                                        823                                             0.884                      126                             116                               9,691    1.2       1.1
  Ireland          7,104                                      7,992                                           0.946                      1,209                           1,360                             17,927   21.7      24.4
  Italy            378,315                                    (378,315)                                       1.045                      81,801                          (81,801)                          17,062   1,395.7   (1,395.7)
  Latvia           2,741                                      2,383                                           0.846                      339                             295                               11,568   3.9       3.4
  Lithuania        4,037                                      3,510                                           0.846                      499                             434                               9,661    4.8       4.2
  Luxembourg       1,870                                      1,831                                           1.212                      550                             538                               17,062   9.4       9.2
  Malta            2,690                                      (2,690)                                         1.045                      582                             \(582\)                           11,111   6.5       6.5
  Netherlands      45,227                                     42,827                                          0.909                      6,919                           6,552                             15,857   109.7     103.9
  Norway           16,759                                     16,759                                          0.866                      2,237                           2,229                             20,051   44.8      44.7
  Poland           6,218                                      7,047                                           0.751                      494                             560                               9,979    4.9       5.6
  Portugal         94,349                                     94,977                                          1.482                      39,573                          39,836                            12,221   483.6     486.8
  Romania          9,098                                      9,320                                           1.455                      3,702                           3,797                             8,187    30.3      31.1
  Slovakia         2,468                                      3,117                                           0.899                      366                             462                               10,037   3.7       4.6
  Slovenia         4,840                                      4,796                                           1.194                      1,382                           1,369                             11,939   16.5      16.3
  Spain            479,775                                    460,023                                         2.136                      347,137                         332,845                           13,558   4,706.5   4,512.7
  Sweden           12,570                                     10,930                                          0.846                      1,555                           1,352                             17,167   26.7      23.2
  Switzerland      6,520                                      3.835                                           0.902                      976                             574                               18,346   17.9      10.5
  United Kingdom   248,647                                    246,200                                         0.81                       26,593                          26,338                            15,324   407.5     403.5
  EU Total         1,926,652                                  1,865,365                                                                  654,551                         639,804                                    9,458     9,256

Data are for European countries with information on methylmercury exposure distributions. For countries without detailed observed data available, the modelled results are given in parenthesis. Sources of underlying data are as in Table  [1](#T1){ref-type="table"}.

Table  [2](#T2){ref-type="table"} presents the estimated IQ losses associated with the MeHg exposures using the linear model, along with the estimates of economic impacts. We used both the observed data and the modelled distributions, and only small differences were seen, thus supporting the notion that the log-normal exposure distribution has an appropriate fit. The greatest benefits accrue for the largest countries with the highest proportions of subjects with exposures above the cut-off level. The total benefit from control of MeHg exposure was the highest for Spain and the lowest for Hungary. On a per capita basis, the calculated benefits are the greatest in the Faroe Islands and the southern countries, Spain, Greece, Portugal, Italy, and Croatia. The total annual benefits in terms of IQ points within the EU were estimated to be in excess of 600,000 per year for the linear DRC. With an average benefit of €13,579 per IQ point, the total economic benefits are estimated to exceed €9,000 million per year. When adjustment for productivity is included, the benefits are somewhat lower for several countries, and the EU total is slightly less than €8,000 million per year (Additional file [3](#S3){ref-type="supplementary-material"}).

For comparison, Table  [3](#T3){ref-type="table"} shows the estimated IQ losses and economic benefits using the log transformed DRF. Due to the steeper curve shape at exposures close to the cut-off point of 0.58 μg/g, the estimated benefits are about 4-fold greater, at about 2.7 million IQ points per year, which correspond to total benefits for the EU of approximately €39,000 million or, after productivity adjustment, €33,000 million.

###### 

**Annual number of births with excess exposure**, **the average log hair**-**Hg concentration**, **and IQ benefit and value from prevention of excess exposure** (**logarithmic dose**-**effect relationship**)

  **Country**      **Number of births above 0**.**58 μg**/**g**   **Average log concentration above 0**.**58 μg**/**g**   **Benefit in IQ points**   **Value of 1 IQ point** (**Euro**)   **Total benefit** (**million Euro**)
  ---------------- ---------------------------------------------- ------------------------------------------------------- -------------------------- ------------------------------------ --------------------------------------
  Austria          3,812                                          −0.157                                                  3,199                      16,044                               51.3
  Belgium          39,686                                         −0.128                                                  35,790                     16,458                               589.0
  Bulgaria         3,186                                          0.128                                                   4,638                      7,529                                34.9
  Croatia          21,769                                         0.142                                                   32,350                     11,320                               366.2
  Cyprus           3,514                                          0.109                                                   4,972                      13,747                               68.3
  Czech Republic   5,143                                          −0.216                                                  3,658                      10,797                               39.5
  Denmark          22,815                                         −0.060                                                  23,932                     20,220                               483.9
  Estonia          1,840                                          −0.214                                                  1,317                      10,339                               13.6
  Faroe Islands    406                                            0.139                                                   600                        20,220                               12.1
  Finland          6,843                                          −0.214                                                  4,897                      17,288                               84.7
  France           405,528                                        −0.053                                                  368,742                    17,363                               6,402.5
  Germany          33,443                                         −0.157                                                  28,060                     15,292                               429.1
  Greece           94,403                                         0.355                                                   183,808                    13,201                               2,426.4
  Hungary          892                                            −0.186                                                  692                        9,691                                6.7
  Ireland          7,104                                          −0.132                                                  6,345                      17,927                               113.7
  Italy            378,315                                        −0.036                                                  416,490                    17,062                               7.106.2
  Latvia           2,741                                          −0.214                                                  1,962                      11,568                               22.7
  Lithuania        4,037                                          −0.214                                                  2,889                      9,661                                27.9
  Luxembourg       1,870                                          0.053                                                   2,419                      17,062                               41.3
  Malta            2,690                                          −0.036                                                  2,961                      11,111                               32.9
  Netherlands      45,227                                         −0.155                                                  38,144                     15,857                               604.8
  Norway           16,759                                         −0.198                                                  12,574                     20,051                               252.1
  Poland           6,218                                          −0.312                                                  3,131                      9,979                                31.2
  Portugal         94,349                                         0.277                                                   167,777                    12,221                               2,050.4
  Romania          9,098                                          0.128                                                   13,245                     8,187                                108.4
  Slovakia         2,468                                          −0.173                                                  1,986                      10,037                               19.9
  Slovenia         4,840                                          0.034                                                   6,061                      11,939                               72.4
  Spain            479,775                                        0.561                                                   1,148,026                  13,558                               15,564.9
  Sweden           12,570                                         −0.214                                                  8,996                      17,167                               154.4
  Switzerland      6,520                                          −0.167                                                  5,329                      18,346                               97.8
  United Kingdom   248,647                                        −0.244                                                  161,816                    15,324                               2,479.7
  EU Total         1,884,563                                                                                              2,645,953                                                       39,061

Data from European countries, sources of underlying data are as in Table  [1](#T1){ref-type="table"}.

Discussion
==========

This study provides for the first time regional European data on economic benefits of controlling MeHg exposure in relation to prevention of developmental neurotoxicity. It relies on data from a multi-country study of hair-Hg concentrations with a high level of quality assurance and with similar population sampling criteria. In addition, available data from other studies have been taken into consideration to provide supplementary information, thereby allowing EU-wide estimates to be calculated. Given the low MeHg exposures in Eastern Europe and the relatively small contributions from Croatia, the Faroe Islands, Norway, and Switzerland, the results suggest that benefits for all of Europe will not be substantially above the benefits calculated for the EU.

Several assumptions and caveats must be acknowledged. The hair-Hg concentration is an established biomarker of human MeHg exposure and is generally considered reliable \[[@B14]\]. We used available data from DEMOCOPHES and other sources, with most studies including only about 120 subjects. The sampling size and strategy may have underestimated the occurrence of uncommon high-level exposures, which would weigh more in the calculation of IQ benefits. Adjustment for this bias is obtained in the modelled distributions, which tended to show slightly greater benefits. Although these calculations rely on an assumption of a log-normal distribution of the exposures, the concurrence of the two sets of estimates support the validity of this assumption.

In calculating the IQ benefits, we used a linear dose-response function for the decrease in IQ at increased prenatal MeHg exposures, and this curve shape is an approximation of unknown validity. As has been documented for lead \[[@B37]\], a logarithmic DRF may be plausible, and a log curve shows a slightly better fit \[[@B16]\]. As the results for the log curve (Table  [3](#T3){ref-type="table"}) are about 4-fold higher than those obtained for the linear curve, the benefits calculated in Table  [2](#T2){ref-type="table"} must be considered likely underestimates. In recent calculations using French data using similar methods \[[@B8]\], the logarithmic curve shape also resulted in substantially higher estimates.

The cut-off level assumed to be 0.58 μg/g hair may also result in underestimated benefits. Recent data from Poland \[[@B20]\], Japan \[[@B21]\] and the United States \[[@B18],[@B19]\] suggest that a lower threshold is likely. If the threshold is indeed lower than we have assumed, the benefits of controlling MeHg exposures will likely be greater, although an additional effort may be required to achieve such lower exposures. Further, given that the much higher tolerable limit of 2.5 μg/g is likely exceeded by 200,000 births in the EU per year, clear benefits will accrue already from controlling the very highest exposures.

The IQ benefits from controlling mercury pollution were translated into economic impacts based on the calculated current life-time income benefits from a higher IQ level. These benefits are mainly based on studies carried out in the United States \[[@B24],[@B38]\], and it is possible that IQ-linked differences in life-time incomes may not be the same in Europe. Adjustment for differences in purchasing power has been included to take this issue into partial account. We used data from 2008 to secure complete data sources; the use of more recent records would change the estimates only slightly. An alternative approach might be to calculate benefits from prevention of specific diseases, e.g. for mental retardation or autism, associated with MeHg exposure. However, the attributable risks associated with increases in MeHg exposure are unknown, and such calculations are therefore uncertain \[[@B10],[@B39]\].

Some sources of imprecision in exposure estimates must be emphasized. Thus, in several cases when exposure information was not available for an EU member state, data from a neighbouring country were used as a proxy. Further, the results reported in DEMOCOPHES and in published reports may not be representative for each country. Although high fish consumers may possibly have been oversampled, it is more likely that the avoidance of known exposure hot-spots resulted in lowered exposure estimates. In addition, especially for small studies, an element of uncertainty exists with regard to the frequencies of the highest exposures, although this problem was addressed by modelling a log-normal distribution of exposures. Temporal variation and time trends may also play a role, especially in regard to older data. We have assumed stable diets, so that any seasonal or other time trends as well as the time dependence of MeHg sensitivity during brain development would not matter for the calculation of impacts.

Our focus on the loss in life-time earnings is similar to the avoidable costs previously calculated in relation to lead exposure \[[@B24]\]. Other costs were ignored, such as direct medical costs linked to treatment or interventions for children with neurodevelopmental disorders. We also neglected indirect costs, such as those related to special education or additional years of schooling for children as a consequence of these disorders, as well as intangible costs. In addition, our study did not consider other avoided direct health care costs in the longer term, such as those potentially related to the treatment of cardiovascular or neurodegenerative effects of MeHg exposure, which could be important for high fish consumers \[[@B2]\], but would be difficult to estimate. Any compensation of the IQ benefit due to special education and other remedies was not taken into account. Overall, the estimates presented in Table  [2](#T2){ref-type="table"} are likely underestimates of the total benefits of MeHg exposure abatement.

Clear differences are apparent between European countries. Seafood and freshwater fish constitute the main source of exposure, but countries with high fish consumption levels, such as Spain and Norway, clearly show great differences in MeHg exposure that are undoubtedly related to the choice of fish species consumed as well as the contamination level. The high exposure levels observed in Spain are in accordance with other studies \[[@B40],[@B41]\]. The elevated exposures in the Faroes are likely related to the occasional consumption of pilot whale meat \[[@B23]\].

Calculations from the United States have resulted in several greatly varying estimates, depending on the DRF assumptions. One comparable estimate put the aggregate economic benefit for each annual birth cohort in the US at \$8.7 billion (range: \$0.7--\$13.9 billion for year 2000) \[[@B10]\]. We recently calculated the annual benefit for the US at about 264,000 IQ points, which would correspond to benefits of approximately \$5 billion \[[@B42]\]. The EU benefits of over 600,000 IQ points are much higher. However, in comparing the figures for the US and the EU, note should be taken that annual number of births in the EU (5.4 million) are 27% greater than the 4.2 million births in the US per year. In addition, MeHg exposures in parts of Europe are higher than in the US \[[@B4]\]. On a global scale, benefit estimates can be extended on the basis of GDP values adjusted for PPP and productivity, but the validity of such calculations is limited by the lack of exposure assessments \[[@B43]\]. However, the present study leaves little doubt that global benefits substantially exceed \$20 billion.

The present study did not aim at calculating annual costs of investments in pollution abatement due to the paucity of available data. Relevant investment costs would consider mercury emissions controls in coal-fired power plants, reduction of mercury usage in the chlorine industry, measures taken in dentistry, plus expenses for recycling and treatment of mercury releases. Some information is available and suggests that one-time expenses may be quickly balanced by the cumulated annual benefits from exposure abatement \[[@B9]\]. However, mercury emissions control needs to be carried out on a global level due to the regional and hemispherical dispersion of mercury releases \[[@B43]\]. These costs would likely have additional socioeconomic yields from better control of mercury emissions, e.g. job creation and modernization of capital equipment.

The control of inorganic mercury emissions will only result in diminished MeHg exposure in the long term, and the benefits will therefore be delayed. As MeHg exposure mainly originates from seafood and freshwater fish, public health advice on dietary choices is an important element of the intervention \[[@B6],[@B44]\]. Due to the essential nutrients present in seafood \[[@B3]\], a reduction in MeHg exposure should not be sought through a decrease or replacement of fish in the diet. A prudent advice would be to maintain fish consumption and minimise the MeHg exposure by consumption of fish known to have lower MeHg concentrations, e.g., smaller species, younger fish, and catches from less polluted waters. Such advice should be directed toward women during pregnancy as the most cost-effective preventive action. Restricted consumption of large, piscivorous fish species may also benefit overfished populations of pelagic fish, such as tuna \[[@B45]\].

The successful completion of the DEMOCOPHES project and the complements from other exposure studies in Europe illustrate the feasibility and usefulness of biological monitoring approaches, in particular when relying on hair samples that may be easily obtained, stored and transported. While such studies have become a routine function in the United States through the National Health And Nutrition Examination Survey \[[@B4]\], and the biomonitoring reports from the Centers for Disease Control and Prevention have become key resources for research on human exposures to environmental chemicals, Europe has lagged behind. Following international policy decisions to decrease global mercury pollution, such human biomonitoring studies will be crucial to monitor the effects of the interventions.

Conclusions
===========

Annual benefits of removing Hg exposure can be estimated to be approximately €9 billion in Europe. While our results support enhanced public policies for the prevention of MeHg exposure, the economic estimates are highly influenced by uncertainties regarding the dose-response relationship. Thus, a logarithmic response curve results in 4-fold higher benefit estimates. In addition, benefits might be underestimated because costs linked to all aspects of neurotoxicity and long-term disease risks have not been considered. These European data and the calculated economic benefits support the need for interventions to minimize exposure to this hazardous pollutant.
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